Corporate Events

CKD Corporation revised dividend guidance for the fiscal year ending March 31, 2027. For fiscal year ending March 31, 2027, the company now expects to pay total dividend of JPY 112.00 per share compared to previous guidance of JPY 95.00 per share. Interim and year-end dividends for the fiscal year ending March 31, 2027 have not been determined yet. Reasons for the Revisions: The Company aims to enhance corporate value through growth investments in human capital, research and development, and the strengthening of its business foundation. At the same time, while maintaining an appropriate balance with capital efficiency, the Company is committed to delivering stable shareholder returns, with a target dividend payout ratio of approximately 40%. Based on this policy, in line with the financial forecasts announced for the fiscal year ending March 31, 2027, the Company announces an annual dividend forecast of JPY 112 per share.

CKD Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company now expects net sales of JPY 193,000 million compared to previous guidance of JPY 180,000 million, operating profit of JPY 28,500 million compared to previous guidance of JPY 24,500 million and profit attributable to owners of parent of JPY 19,000 million compared to previous guidance of JPY 16,300 million and basic earnings per share of JPY 284.29 compared to previous guidance of JPY 243.89. Reasons for the Revisions: The consolidated financial forecasts for the fiscal year ending March 31, 2027 announced on May 15, 2026 have been revised upward as above. This decision is based on the fact that demand in the semiconductor-related market within the Components segment significantly exceeded initial projections during the three months ended June 30, 2026, as well as an assessment of current order trends.

CKD Corporation reported earnings results for the first quarter ended June 30, 2026. For the first quarter, the company reported sales was JPY 49,108 million compared to JPY 36,253 million a year ago. Net income was JPY 5,686 million compared to JPY 2,477 million a year ago. Basic earnings per share from continuing operations was JPY 85.09 compared to JPY 37.09 a year ago.

CKD Corporation, ¥ 48.0, Cash Dividend, Sep-29-2026

CKD Corporation, Q1 2027 Earnings Call, Aug 10, 2026

CKD Corporation announces that it has resolved, at a meeting of the Board of Directors held May 15, 2026, to submit a proposal regarding partial amendment to the Articles of Incorporation to the 106th Annual General Meeting of Shareholders of the Company to be held on June 26, 2026. The Company has decided to transition from a company with an Audit & Supervisory Board to a company with an Audit and Supervisory Committee, subject to the approval of the 106th Annual General Meeting of Shareholders of the Company to be held in June 2026 with the following aim: to strengthen the supervisory function of the Board of Directors and further enhance corporate governance through the strengthening of the monitoring system by including Audit and Supervisory Committee Members, who are in charge of auditing the execution of duties by Directors, among members of the Board of Directors; and to speed up the decision-making of management and work on further improvement of corporate value by making it possible to delegate decisions on the execution of important business operations from the Board of Directors to Directors. In line with this transition, amendments necessary for the transition to a company with an Audit and Supervisory Committee are to be made, including the establishment of new provisions regarding Directors serving as Audit and Supervisory Committee Members and the Audit and Supervisory Committee, and the deletion of provisions regarding Audit & Supervisory Board Members and the Audit & Supervisory Board. Amendments to Article 28, Paragraph 2 of the Articles of Incorporation are to be made so that liability limitation agreements with Directors other than Executive Directors, etc., may be concluded for the purpose of continuously securing individuals who are competent as Directors. Other necessary amendments, such as the revision of wording in line with the above amendments, are to be made. The details of the amendment are as follows. The Company shall have the general meeting of shareholders, directors, and the other organizations as follows: (1) Board of Directors (2) Audit and Supervisory Committee (3) Accounting Auditors. The Company shall have no more than ten (10) Directors (excluding Directors who are Audit and Supervisory Committee members). The Company shall have no more than four (4) Directors who are Audit and Supervisory Committee members. The election of Directors under the preceding paragraph shall be conducted separately for Directors who are Audit and Supervisory Committee members and for other Directors. The term of office of Directors (excluding Directors who are Audit and Supervisory Committee members) shall expire upon the conclusion of the ordinary general meeting of shareholders in respect of the last business year ending within one (1) year after their assumption of office. The term of office of Directors who are Audit and Supervisory Committee members shall expire upon the conclusion of the ordinary general meeting of shareholders in respect of the last business year ending within two (2) years after their assumption of office. The Board of Directors shall, by its resolution, appoint the Representative Directors from among Directors (excluding Directors who are Audit and Supervisory Committee members). The Board of Directors may, by its resolution, appoint one each of Chairperson of the Board of Directors and President-Director, and a certain number of Executive Vice President-Directors, Executive Managing Directors and Managing Directors from among Directors (excluding Directors who are Audit and Supervisory Committee members). The remunerations, bonus and other property benefit to be received as compensation for the performance of the duty by Directors from the Company shall be determined separately for Directors who are Audit and Supervisory Committee members and for other Directors by a resolution of a general meeting of shareholders. The notice of a meeting of the preceding paragraph shall be dispatched to each Director three (3) days in advance to the date for such meeting, provided, however, that in case of urgency, such period may be shortened. Pursuant to the provisions of Article 399-13, Paragraph 6 of the Companies Act, the Company may, by a resolution of the Board of Directors, delegate all or part of the decisions on important business execution (excluding the matters described in each item of Paragraph 5 of the same Article) to Directors. The Company may enter into an agreement with Directors (excluding those who are executive directors, etc.) which limits liability for damages stipulated in Article 423, Paragraph 1 of Companies Act in accordance with the provisions of Article 427, Paragraph 1 of Companies Act; provided, however, that the limitation of liability under such agreement shall be limited to the extent permitted by law. The Audit and Supervisory Committee may, by its resolution, elect the full-time Audit and Supervisory Committee members. The notice of a meeting of the Audit and Supervisory Committee shall be dispatched to each Audit and Supervisory Committee member three (3) days in advance to the date for such meeting, provided, however, that in case of urgency, such period may be shortened. All the matters related to the Audit and Supervisory Committee shall, in addition to by laws or ordinances or by the Articles of Incorporation, be in accordance with the Rules and Regulations of the Audit and Supervisory Committee stipulated by the Audit and Supervisory Committee. The Company may, by a resolution of the Board of Directors, exempt Audit & Supervisory Board Members (including a person who was an Audit & Supervisory Board Member) from their liabilities for damages stipulated in Article 423, Paragraph 1 of the Companies Act to the extent permitted by law with respect to acts performed prior to the conclusion of the 106th Annual General Meeting of Shareholders. Date of the General Meeting of Shareholders to amend the Articles of Incorporation: June 26, 2026 (scheduled). Effective date of the amendment to the Articles of Incorporation: June 26, 2026 (scheduled).

CKD Corporation provided dividend guidance for the Fiscal year ending March 31, 2027. For the year, the company expects dividend of JPY 95.00 per share.

CKD Corporation provided consolidated earnings forecast for the full fiscal year ending March 31, 2027. For the year, the company expected Net sales of JPY 180,000 million; Operating profit of JPY 24,500 million; Profit attributable to owners of parent of JPY 16,300 million; and Basic earnings per share of JPY 243.88.

CKD Corporation announced retirement of Koichi Hayashi as External Director Toshiaki Sugiura, Toshiaki Sugiura as Standing Audit & Supervisory Board Member and Kiyoshi Miura, Tsuyoshi takeuchi as External Audit and Supervisory Board Member. The New Title of Toshiaki Sugiura will be Senior Adviser.

CKD Corporation declared dividend of JPY 49 per share for the fiscal year ending March 31, 2026 compared to JPY 42 per share a year ago. Effective date is June 11, 2026. Base date is March 31, 2026. Based on this policy, the year-end dividend for the fiscal year ending March 31, 2026, has been increased by 14 yen from the previous forecast of 35 yen to 49 yen per share.

CKD Corporation announced that they will report Q1, 2027 results on Aug 10, 2026

CKD Corporation expected to report Q1 2027 results on August 14, 2026. This event was calculated by S&P Global (Created on May 15, 2026).

CKD Corporation, Annual General Meeting, Jun 26, 2026.

CKD Corporation, Board Meeting, May 15, 2026. Agenda: To consider the Notice Regarding Partial Amendment to the Articles of Incorporation in Line with the Transition to Company with Audit and Supervisory Committee.

CKD Corporation, Board Meeting, Jun 26, 2026. Agenda: To consider the Personnel Affaires of Officers and Change of Executive Officers in Line with Transition to Company with Audit and Supervisory Committee.

CKD Corporation, 2026 Earnings Call, May 15, 2026

CKD Corporation announced that they will report fiscal year 2026 results on May 15, 2026

CKD Corporation hereby announces that it has resolved, at a meeting of the Board of Directors held on March 27, 2026, to transition to a Company with an Audit and Supervisory Committee subject to the approval of the 106th Annual General Meeting of Shareholders of the Company to be held in June 2026. The Company aims the following: to strengthen the supervisory function of the Board of Directors and further enhance corporate governance through the strengthening of the monitoring system by having Audit and Supervisory Committee members, who are in charge of auditing the execution of duties by Directors, as members of the Board of Directors; and to accelerate the speed of management decision-making and work to further improve corporate value by making it possible to delegate decisions on the execution of important business operations from the Board of Directors to Directors. The Company plans to transition to a Company with an Audit and Supervisory Committee upon approval of amendments to the Articles of Incorporation necessary for the transition at the 106th Annual General Meeting of Shareholders to be held in June 2026. Details of the amendments to the Articles of Incorporation, the personnel affairs of officers, etc. associated with the transition will be announced as soon as they are determined.

CKD Corporation, Board Meeting, Mar 27, 2026. Agenda: To consider transition to a Company with an Audit and Supervisory Committee.

CKD Corporation reported earnings results for the nine months ended December 31, 2025. For the nine months, the company reported sales was JPY 112,016 million compared to JPY 115,082 million a year ago. Net income was JPY 8,838 million compared to JPY 9,475 million a year ago. Basic earnings per share from continuing operations was JPY 132.28 compared to JPY 141.91 a year ago.

CKD Corporation, Board Meeting, Feb 13, 2026. Agenda: To consider to dispose of treasury stock as restricted stock to executive officers.

CKD Corporation, Q3 2026 Earnings Call, Feb 13, 2026

CKD Corporation expected to report Fiscal Year 2026 results on May 15, 2026. This event was calculated by S&P Global (Created on January 1, 2026).

CKD Corporation announced that they will report Q3, 2026 results on Feb 13, 2026

CKD Corporation revised consolidated earnings forecast for the fiscal year ending March 31, 2026. For the year, the company revises Net sales of JPY 151,000 million; Operating profit of JPY 16,600 million; Profit attributable to owners of parent of JPY 11,200 million; and Basic earnings per share of JPY 167.63 compared to previous guidance of net sales of JPY 156,000 million; Operating profit of JPY 19,000 million; Profit attributable to owners of parent of JPY 13,100 million; and Basic earnings per share of JPY 196.07. Reasons for the revisions: The outlook for the global economy remains uncertain due to policy developments in various countries, as well as geopolitical risk and fluctuations in interest rates and foreign exchange rates. Meanwhile, in anticipation of further expansion of demand for component products, the CKD Group has strengthened its production systems both domestically and internationally. Initial forecasts anticipated that demand for semiconductor-related components would increase from the second half of the year. However, as the current pace of demand recovery is slow, a full recovery is expected in fiscal year 2026 or later.

CKD Corporation, ¥ 35.0, Cash Dividend, Mar-30-2026

CKD Corporation expected to report Q3 2026 results on February 13, 2026. This event was calculated by S&P Global (Created on November 14, 2025).

CKD Corporation, Q2 2026 Earnings Call, Nov 14, 2025